Evidence map›Paper›PMID 38448381›Full record

ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2023

Research progress regarding

Qi Jia, Qingsong Ding, Kangmei Shao, Jianzhong Dang, Fan Zhang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Qi JiaSecond Clinical Medical School, Lanzhou University, Lanzhou 730030. 1223684838@qq.com.
Qingsong DingSecond Clinical Medical School, Lanzhou University, Lanzhou 730030.
Kangmei ShaoSecond Clinical Medical School, Lanzhou University, Lanzhou 730030.
Jianzhong DangDepartment of Surgical Oncology, Second Hospital, Lanzhou University, Lanzhou 730030.
Fan ZhangDepartment of Surgical Oncology, Second Hospital, Lanzhou University, Lanzhou 730030. zhangf16@lzu.edu.cn.
Lanzhou University Second Hospital · CN

Funding

the Cuiying Scientific and Technological Innovation Program of the Second Hospital of Lanzhou University CY2022-YB-A04 and CY2023-MS-B17the Cuiying Scientific Training Program for Undergraduates of the Second Hospital of Lanzhou University CYXZ2021-14the Fundamental Research Funds for the Central Universities of Lanzhou University lzujbky-2023-stlt01
6 · The paper itself

Abstract

Cytochrome P450 family 3 subfamily A (CYP3A), a major member of cytochrome P450 (CYP) family, is one of the most important drug metabolizing enzymes in human. CYP3A includes 4 gene subtypes (

Indexed as

Stomach NeoplasmsCytochrome P-450 CYP3AHumansCytochrome P-450 CYP3Acytochrome P450cytochrome P450 3Acytochrome P450 3A4drug metabolizing enzymesgastric cancertumor

Identifiers

PMID38448381
PMCPMC10930750
OpenAlexW4394758815

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.